Association of metabolic syndrome with prostate cancer diagnosis and aggressiveness in patients undergoing transrectal prostate biopsy
https://doi.org/10.4081/aiua.2021.3.291
Accepted: July 10, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Introduction and objective: Even though the only established risk factors for prostate cancer (PCa) are age, ethnic origin and family history, there are data suggesting that environmental factors, such as the presence of metabolic syndrome (MetS), may also play a role in the etiology of the disease. The aim of this study is to correlate MetS with PCa diagnosis and Gleason score (GS) in patients undergoing transrectal ultrasound guided prostate biopsy.
Materials and methods: This is a prospective, single-center study including 378 patients who underwent transrectal ultrasound guided prostate biopsy in our department during the years from 2018 to 2019. Patients were divided into two groups according to the presence of PCa. Group A included 197 patients diagnosed with PCa while Group B consisted of 181 patients without PCa in their biopsy result. Multiple variables such as the presence of MetS and its components were evaluated in correlation to the presence of PCa and PCa characteristics. Statistical analysis was performed using the IBM SPSS Statistics v.23 program.
Results: Mean PSA value was 8.7 ng/dl in the PCa group and 7.1 ng/dl in the non PCa group, respectively. MetS was diagnosed in 108 patients (54.8%) with PCa and 80 patients (44.2%) without PCa and the difference was statistically significant. Hypertriglyceridemia was the MetS component with statistically higher frequency in PCa patients. Furthermore, the prevalence of MetS was higher in higher Gleason score PCa (GS ≥ 4+3) patients vs lower Gleason score PCa (GS ≤ 3+4) patients. More specifically, MetS, hypertriglyceridemia, and low HDL levels were independent factors associated with higher Gleason score PCa (GS ≥ 4+3).
Conclusions: Patients suffering from MetS who undergo prostate biopsy present with higher rates of PCa diagnosis and higher GS in comparison with patients with a normal metabolic profile.
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Nech 2009;2:231-237. DOI: https://doi.org/10.1242/dmm.001180
Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399-404. DOI: https://doi.org/10.1210/jc.2006-0513
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-2449. DOI: https://doi.org/10.2337/diacare.27.10.2444
Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 2007;86:s817–s819. DOI: https://doi.org/10.1093/ajcn/86.3.817S
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569–578. DOI: https://doi.org/10.1016/S0140-6736(08)60269-X
Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010;47:87–95. DOI: https://doi.org/10.1007/s00592-010-0187-3
Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid altering therapy. J Am Coll Cardiol 2010; 55:2846–2854. DOI: https://doi.org/10.1016/j.jacc.2009.12.069
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;1;136:E359-86. DOI: https://doi.org/10.1002/ijc.29210
Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132-139. DOI: https://doi.org/10.1007/BF03346748
Blanc-Lapierre A, Spence A, Karakiewicz PI, et al. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015;18;15:913. DOI: https://doi.org/10.1186/s12889-015-2260-x
Hsing AW, Sakoda LC, Chua Jr S. Obesity, metabolic syndrome and prostate cancer. Am J Clin Nutr 2007;86:843-857. DOI: https://doi.org/10.1093/ajcn/86.3.843S
Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51. DOI: https://doi.org/10.1016/S0084-3873(09)79550-1
Fragkoulis C, Glykas I, Gkialas I, et al. The role of nutrition in the prevention of prostatic adenocarcinoma. J BUON. 2017;22:1085-1086.
Xiang YZ, Xiong H, Cui ZL, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. 2013;13;32:9. DOI: https://doi.org/10.1186/1756-9966-32-9
De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-570. DOI: https://doi.org/10.1016/j.eururo.2011.11.013
Bhindi B, Locke J, Alibhai SM, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67:64-70. DOI: https://doi.org/10.1016/j.eururo.2014.01.040
Gustafson B, Hammarstedt A, Andersson CX, et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2276-2283. DOI: https://doi.org/10.1161/ATVBAHA.107.147835
Buschemeyer III WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol, 2007;52:331-343. DOI: https://doi.org/10.1016/j.eururo.2007.04.069
Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012-20. DOI: https://doi.org/10.1016/j.eururo.2014.04.027
Freedland SJ, Hamilton RJ, Gerber L, et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2013; 16:254-9. DOI: https://doi.org/10.1038/pcan.2013.10
YuPeng L, YuXue Z, PengFei L, et al. Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies. Cancer Epidemiol Biomarkers Prev. 2015; 24:1086-93. DOI: https://doi.org/10.1158/1055-9965.EPI-14-1329
Vidal AC, Howard LE, Moreira DM, et al. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014; 23:2936-42. DOI: https://doi.org/10.1158/1055-9965.EPI-14-0795
Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101:2476-2481. DOI: https://doi.org/10.1073/pnas.0308671100
De Nunzio C, Freedland SJ, Miano R, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011;71:1492–1498. DOI: https://doi.org/10.1002/pros.21364
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
